SPYRE THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
SPYRE THERAPEUTICS, INC. (SYRE) had Debt Securities, Available-for-sale, Amortized Cost of $985.74 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $985.74M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $645.05M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $669.94M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $420.51M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $985.74M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $645.05M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $669.94M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $420.51M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $444.47M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $515.68M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $513.51M 10-K · filed 2026-02-19 |
| 2024-09-30 | $341.25M 10-Q/A · filed 2024-11-18 |
| 2024-06-30 | $381.44M 10-Q/A · filed 2024-11-18 |
| 2024-03-31 | $257.49M 10-Q/A · filed 2024-11-18 |
| 2023-12-31 | $150.10M 10-K · filed 2025-02-27 |
| 2023-09-30 | $113.12M 10-Q · filed 2023-11-09 |
| 2023-03-31 | $3.23M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $20.88M 10-K/A · filed 2024-11-18 |
| 2022-09-30 | $34.80M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $51.26M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $52.25M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $78.02M 10-K · filed 2023-03-02 |
| 2021-09-30 | $87.78M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $93.83M 10-Q · filed 2021-08-05 |
| 2020-12-31 | $56.18M 10-K · filed 2022-03-08 |
| 2020-09-30 | $85.74M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $91.98M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $36.53M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $52.65M 10-K · filed 2021-03-18 |
| 2019-09-30 | $64.08M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $80.04M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $38.06M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $52.08M 10-K · filed 2020-02-24 |
| 2018-09-30 | $50.24M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $51.67M 10-Q · filed 2018-08-09 |
| 2017-12-31 | $37.58M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |